NASDAQ:LNSR - Nasdaq - US52634L1089 - Common Stock - Currency: USD
NASDAQ:LNSR (4/21/2025, 8:00:00 PM)
13.79
-0.12 (-0.86%)
The current stock price of LNSR is 13.79 USD. In the past month the price decreased by -6.95%. In the past year, price increased by 325.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.17 | 225.27B | ||
ISRG | INTUITIVE SURGICAL INC | 63.89 | 167.79B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.28 | 138.41B | ||
SYK | STRYKER CORP | 27.86 | 129.62B | ||
MDT | MEDTRONIC PLC | 15.32 | 104.91B | ||
BDX | BECTON DICKINSON AND CO | 14.13 | 56.45B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.41 | 40.68B | ||
IDXX | IDEXX LABORATORIES INC | 36.15 | 32.95B | ||
RMD | RESMED INC | 23.85 | 30.97B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 13.47 | 27.69B | ||
DXCM | DEXCOM INC | 40.07 | 25.92B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 14.83 | 21.89B |
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR INC
2800 Discovery Drive, Suite 100
Orlando FLORIDA 32826 US
CEO: Nicholas Curtis
Employees: 130
Company Website: https://www.lensar.com/
Investor Relations: http://ir.lensar.com/overview/default.aspx
Phone: 18885367271
The current stock price of LNSR is 13.79 USD. The price decreased by -0.86% in the last trading session.
The exchange symbol of LENSAR INC is LNSR and it is listed on the Nasdaq exchange.
LNSR stock is listed on the Nasdaq exchange.
7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 10.95% is expected in the next year compared to the current price of 13.79. Check the LENSAR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LENSAR INC (LNSR) has a market capitalization of 162.58M USD. This makes LNSR a Micro Cap stock.
LENSAR INC (LNSR) currently has 130 employees.
LENSAR INC (LNSR) has a support level at 13.63 and a resistance level at 13.87. Check the full technical report for a detailed analysis of LNSR support and resistance levels.
The Revenue of LENSAR INC (LNSR) is expected to grow by 31.82% in the next year. Check the estimates tab for more information on the LNSR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LNSR does not pay a dividend.
LENSAR INC (LNSR) will report earnings on 2025-05-07, before the market open.
LENSAR INC (LNSR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.72).
The outstanding short interest for LENSAR INC (LNSR) is 1.13% of its float. Check the ownership tab for more information on the LNSR short interest.
ChartMill assigns a technical rating of 10 / 10 to LNSR. When comparing the yearly performance of all stocks, LNSR is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LNSR. LNSR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LNSR reported a non-GAAP Earnings per Share(EPS) of -2.72. The EPS decreased by -51.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -47.37% | ||
ROE | -168.42% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 46% to LNSR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 85.38% and a revenue growth 31.82% for LNSR